Experts Whitney Marvin, MD, and Jinoos Yazdany, MD, discuss how to find synergy between work & career to better manage work/life conflicts and avoid burnout as rheumatologists.
Search results for: pediatric
Management Updates for a Spectrum of Systemic Autoinflammatory Diseases
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
Linda Hiraki, MD, ScD, Seeks Advocacy, Collaborations via the Committee on Research
After three years on the Committee for Research, Linda Hiraki, MD, ScD, has stepped into the role of chair. During her term, she aims to foster global connections to advance and expand the positive impact of rheumatology research.
The 2023 ARP Merit Awards
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
What Changes May the Next Decade Bring to Rheumatology?
Is it 2024 already? It seems like yesterday that I stuffed all my earthly belongings into my black Volkswagen Jetta and headed from Lexington, Ky., to Iowa City, Iowa, to start my rheumatology fellowship.1 That was 10 years ago. Now, in 2024, as I go online—particularly on social media—and see the various happy, smiling faces…
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Insight into the FDA Approval of Ustekinumab Biosimilar
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Updates from AMA House of Delegates 2023 Interim Meeting
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.
Heterogeneity in Lupus: Lessons from the Autoimmune Centers of Excellence
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
Striving for Equity
SAN DIEGO—At ACR Convergence 2023, panelists provided guidance for reducing disparities and improving health equity for patients who are negatively impacted by social determinants of health.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 109
- Next Page »